Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.
about
Biochemical evaluation of the anticancer potential of the polyamine-based nanocarrier Nano11047Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing ProgramHistone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism.Development of treatment strategies for advanced neuroblastoma.Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.Oil for the cancer engine: The cross-talk between oncogenic signaling and polyamine metabolism.
P2860
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Initial testing (stage 1) of t ...... c preclinical testing program.
@en
type
label
Initial testing (stage 1) of t ...... c preclinical testing program.
@en
prefLabel
Initial testing (stage 1) of t ...... c preclinical testing program.
@en
P2093
P2860
P50
P356
P1476
Initial testing (stage 1) of t ...... ic preclinical testing program
@en
P2093
Christopher L Morton
E Anders Kolb
Hernan Carol
John M Maris
Malcolm A Smith
Peter J Houghton
Stephen T Keir
P2860
P304
P356
10.1002/PBC.22797
P577
2011-02-25T00:00:00Z